SZN 413
Alternative Names: SZN-413Latest Information Update: 08 Apr 2024
At a glance
- Originator Surrozen
- Class Bispecific antibodies; Eye disorder therapies
- Mechanism of Action Wnt signalling pathway stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Diabetic retinopathy; Wet age-related macular degeneration